

Overcoming Disease Recurrence and Treatment Resistance in HER2-Positive Metastatic Tumors – Tweeterial #3 References

Tweet 5

ENHERTU® (fam-trastuzumab deruxtecan-nxki) [prescribing information]. Daiichi Sankyo, Inc. Approved 2019. Revised January 2021.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Esophageal and Esophagogastric Cancers (v4.2021). Updated August 3, 2021. Accessed September 8, 2021. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Gastric Cancer (v5.2021). Updated October 6, 2021. Accessed October 15, 2021. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf

Tweet 6

Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. *N Engl J Med*. 2020;382(25):2419-2430. doi:10.1056/NEJMoa2004413

Tweet 7

Catenacci DV, Rosales M, Chung HC, et al. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. *Future Oncol*. 2021;17(10):1155-1164. doi:10.2217/fon-2020-1007

ClinicalTrials.gov. Combination margetuximab, INCMGA00012, MGD013, and chemotherapy phase 2/3 trial in HER2+ gastric/GEJ cancer (MAHOGANY). NCT04082364. Updated November 8, 2021. Accessed November 10, 2021. <https://www.clinicaltrials.gov/ct2/show/NCT04082364>

ClinicalTrials.gov. Trastuzumab deruxtecan for subjects with HER2-positive gastric cancer or gastro-esophageal junction adenocarcinoma after progression on or after a trastuzumab-containing regimen (DESTINY-Gastric04). NCT04704934. Updated September 10, 2021. Accessed November 10, 2021. <https://clinicaltrials.gov/ct2/show/NCT04704934>

ClinicalTrials.gov. Tucatinib, trastuzumab, ramucirumab, and paclitaxel versus paclitaxel and ramucirumab in previously treated HER2+ gastroesophageal cancer (MOUNTAINEER-02). NCT04499924. Updated October 5, 2021. Accessed November 10, 2021. <https://www.clinicaltrials.gov/ct2/show/NCT04499924>

Tweet 8

ClinicalTrials.gov. Trastuzumab deruxtecan for subjects with HER2-positive gastric cancer or gastro-esophageal junction adenocarcinoma after progression on or after a trastuzumab-containing regimen (DESTINY-Gastric04). NCT04704934. Updated September 10, 2021. Accessed November 10, 2021. <https://clinicaltrials.gov/ct2/show/NCT04704934>

Shitara K, Seraj J, Franke FA, et al. 1436TiP Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study. *Ann Oncol*. 2021;32:S1073. doi:10.1016/j.annonc.2021.08.1545

Tweet 9

ClinicalTrials.gov. Tucatinib, trastuzumab, ramucirumab, and paclitaxel versus paclitaxel and ramucirumab in previously treated HER2+ gastroesophageal cancer (MOUNTAINEER-02). NCT04499924. Updated October 5, 2021. Accessed November 10, 2021. <https://www.clinicaltrials.gov/ct2/show/NCT04499924>

Strickler JH, Nakamura Y, Yoshino T, et al. MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—trial in progress. *J Clin Oncol*. 2021;39(3_suppl):TPS252-TPS252. doi:10.1200/JCO.2021.39.3_suppl.TPS252

Tweet 11

Catenacci DV, Rosales M, Chung HC, et al. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. *Future Oncol*. 2021;17(10):1155-1164. doi:10.2217/fon-2020-1007

ClinicalTrials.gov. Combination margetuximab, INCMGA00012, MGD013, and chemotherapy phase 2/3 trial in HER2+ gastric/GEJ cancer (MAHOGANY). NCT04082364. Updated November 8, 2021. Accessed November 10, 2021. <https://www.clinicaltrials.gov/ct2/show/NCT04082364>

Glossary

ADC, antibody-drug conjugate
AE, adverse event
chemo, chemotherapy
CI, confidence interval
CNS, central nervous system
DCR, disease control rate
DOR, duration of response
FC, fragment crystallizable
GEC, gastroesophageal junction adenocarcinoma
GC, gastric cancer
HER2, human epidermal growth factor receptor 2
HR, hazard ratio
IgG1, immunoglobulin G1
IO, immunotherapy
LA, locally advanced
LAG-3, lymphocyte activation gene 3
MOA, mechanism of action
mOS, median overall survival
mPFS, median progression-free survival
ORR, objective response rate
OS, overall survival
PD-1, programmed cell death receptor 1
PFS, progression-free survival
QOL, quality of life
T-DXd, trastuzumab deruxtecan
w/, with